echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > New oral TYK2 inhibitor! Nuocheng Jianhua Class 1 New Drug Clinical Application Accepted

    New oral TYK2 inhibitor! Nuocheng Jianhua Class 1 New Drug Clinical Application Accepted

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    SourceGuanlan Pharmaceutical

    On February 26, Nuocheng Jianhua announced that its new drug clinical trial application for its new Tyrosine Kinase 2 (TYK2) inhibitor ICP-332 has been accepted by the China National Medical Products Administration (NMPA).


    TYK2 is a member of the Janus kinase (JAK) family of proteins.


    ICP-332 is a more efficient and selective new type of TYK2 inhibitor, with strong inhibitory activity on TYK2.


    According to the press release, the ICP-332 clinical trial application was accepted by NMPA, and it is expected to become Nuocheng Jianhua's fifth innovative drug to enter the clinical stage.


    Nuocheng Jianhua was founded in 2015 by Dr.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.